Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

Marlo Blazer, Christina Wu, Richard M. Goldberg, Gary Phillips, Carl Schmidt, Peter Muscarella, Evan Wuthrick, Terrence M. Williams, Joshua Reardon, E. Christopher Ellison, Mark Bloomston, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Background: For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden. Because of reported response rates exceeding 30 %, the authors began to use a modified (m) FOLFIRINOX regimen for patients with advanced nonmetastatic disease aimed at downstaging for resection. This report describes their experience with mFOLFIRINOX and aggressive surgical resection. Methods: Between January 2011 and August of 2013, 43 patients with borderline resectable pancreatic cancer (BRPC, n = 18) or locally advanced pancreatic cancer (LAPC, n = 25) were treated with mFOLFIRINOX (no bolus 5-FU, no LV, and decreased IRI). Radiation was used based on response and intended surgery. Charts were retrospectively reviewed to assess response, toxicities, and extent of resection when possible. Results: The most common grade 3/4 toxicity was diarrhea in six patients (14 %) with no grade 3/4 neutropenia or thrombocytopenia. Resection was attempted in 31 cases (72 %) and accomplished in 22 cases (51.1 %) including 11 of 25 LAPC cases (44 %). Vascular resection was required in 4 cases (18 %), with R0 resection in 86.4 % of the resections. Complications occurred in 6 cases (27 %), with no perioperative deaths. The median progression-free survival period was 18 months if the resection was achieved compared with 8 months if no resection was performed (p < 0.001). Conclusion: Neoadjuvant mFOLFIRINOX is an effective, well-tolerated regimen for patients with advanced nonmetastatic pancreatic cancer. When mFOLFIRINOX is coupled with aggressive surgery, high resection rates are possible even when the initial imaging shows locally advanced disease. Although data are still maturing, resection appears to offer at least a progression-free survival advantage.

Original languageEnglish (US)
Pages (from-to)1153-1159
Number of pages7
JournalAnnals of Surgical Oncology
Volume22
Issue number4
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Pancreas
Adenocarcinoma
irinotecan
Pancreatic Neoplasms
Fluorouracil
oxaliplatin
Leucovorin
gemcitabine
Disease-Free Survival
Neutropenia
Tumor Burden
Thrombocytopenia
Blood Vessels
Diarrhea
Survival Rate
Radiation

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Cite this

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. / Blazer, Marlo; Wu, Christina; Goldberg, Richard M.; Phillips, Gary; Schmidt, Carl; Muscarella, Peter; Wuthrick, Evan; Williams, Terrence M.; Reardon, Joshua; Christopher Ellison, E.; Bloomston, Mark; Bekaii-Saab, Tanios.

In: Annals of Surgical Oncology, Vol. 22, No. 4, 2015, p. 1153-1159.

Research output: Contribution to journalArticle

Blazer, M, Wu, C, Goldberg, RM, Phillips, G, Schmidt, C, Muscarella, P, Wuthrick, E, Williams, TM, Reardon, J, Christopher Ellison, E, Bloomston, M & Bekaii-Saab, T 2015, 'Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas', Annals of Surgical Oncology, vol. 22, no. 4, pp. 1153-1159. https://doi.org/10.1245/s10434-014-4225-1
Blazer, Marlo ; Wu, Christina ; Goldberg, Richard M. ; Phillips, Gary ; Schmidt, Carl ; Muscarella, Peter ; Wuthrick, Evan ; Williams, Terrence M. ; Reardon, Joshua ; Christopher Ellison, E. ; Bloomston, Mark ; Bekaii-Saab, Tanios. / Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 4. pp. 1153-1159.
@article{c142bd7bf74e402aa940d61bd84c2e5e,
title = "Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas",
abstract = "Background: For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden. Because of reported response rates exceeding 30 {\%}, the authors began to use a modified (m) FOLFIRINOX regimen for patients with advanced nonmetastatic disease aimed at downstaging for resection. This report describes their experience with mFOLFIRINOX and aggressive surgical resection. Methods: Between January 2011 and August of 2013, 43 patients with borderline resectable pancreatic cancer (BRPC, n = 18) or locally advanced pancreatic cancer (LAPC, n = 25) were treated with mFOLFIRINOX (no bolus 5-FU, no LV, and decreased IRI). Radiation was used based on response and intended surgery. Charts were retrospectively reviewed to assess response, toxicities, and extent of resection when possible. Results: The most common grade 3/4 toxicity was diarrhea in six patients (14 {\%}) with no grade 3/4 neutropenia or thrombocytopenia. Resection was attempted in 31 cases (72 {\%}) and accomplished in 22 cases (51.1 {\%}) including 11 of 25 LAPC cases (44 {\%}). Vascular resection was required in 4 cases (18 {\%}), with R0 resection in 86.4 {\%} of the resections. Complications occurred in 6 cases (27 {\%}), with no perioperative deaths. The median progression-free survival period was 18 months if the resection was achieved compared with 8 months if no resection was performed (p < 0.001). Conclusion: Neoadjuvant mFOLFIRINOX is an effective, well-tolerated regimen for patients with advanced nonmetastatic pancreatic cancer. When mFOLFIRINOX is coupled with aggressive surgery, high resection rates are possible even when the initial imaging shows locally advanced disease. Although data are still maturing, resection appears to offer at least a progression-free survival advantage.",
author = "Marlo Blazer and Christina Wu and Goldberg, {Richard M.} and Gary Phillips and Carl Schmidt and Peter Muscarella and Evan Wuthrick and Williams, {Terrence M.} and Joshua Reardon and {Christopher Ellison}, E. and Mark Bloomston and Tanios Bekaii-Saab",
year = "2015",
doi = "10.1245/s10434-014-4225-1",
language = "English (US)",
volume = "22",
pages = "1153--1159",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

AU - Blazer, Marlo

AU - Wu, Christina

AU - Goldberg, Richard M.

AU - Phillips, Gary

AU - Schmidt, Carl

AU - Muscarella, Peter

AU - Wuthrick, Evan

AU - Williams, Terrence M.

AU - Reardon, Joshua

AU - Christopher Ellison, E.

AU - Bloomston, Mark

AU - Bekaii-Saab, Tanios

PY - 2015

Y1 - 2015

N2 - Background: For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden. Because of reported response rates exceeding 30 %, the authors began to use a modified (m) FOLFIRINOX regimen for patients with advanced nonmetastatic disease aimed at downstaging for resection. This report describes their experience with mFOLFIRINOX and aggressive surgical resection. Methods: Between January 2011 and August of 2013, 43 patients with borderline resectable pancreatic cancer (BRPC, n = 18) or locally advanced pancreatic cancer (LAPC, n = 25) were treated with mFOLFIRINOX (no bolus 5-FU, no LV, and decreased IRI). Radiation was used based on response and intended surgery. Charts were retrospectively reviewed to assess response, toxicities, and extent of resection when possible. Results: The most common grade 3/4 toxicity was diarrhea in six patients (14 %) with no grade 3/4 neutropenia or thrombocytopenia. Resection was attempted in 31 cases (72 %) and accomplished in 22 cases (51.1 %) including 11 of 25 LAPC cases (44 %). Vascular resection was required in 4 cases (18 %), with R0 resection in 86.4 % of the resections. Complications occurred in 6 cases (27 %), with no perioperative deaths. The median progression-free survival period was 18 months if the resection was achieved compared with 8 months if no resection was performed (p < 0.001). Conclusion: Neoadjuvant mFOLFIRINOX is an effective, well-tolerated regimen for patients with advanced nonmetastatic pancreatic cancer. When mFOLFIRINOX is coupled with aggressive surgery, high resection rates are possible even when the initial imaging shows locally advanced disease. Although data are still maturing, resection appears to offer at least a progression-free survival advantage.

AB - Background: For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden. Because of reported response rates exceeding 30 %, the authors began to use a modified (m) FOLFIRINOX regimen for patients with advanced nonmetastatic disease aimed at downstaging for resection. This report describes their experience with mFOLFIRINOX and aggressive surgical resection. Methods: Between January 2011 and August of 2013, 43 patients with borderline resectable pancreatic cancer (BRPC, n = 18) or locally advanced pancreatic cancer (LAPC, n = 25) were treated with mFOLFIRINOX (no bolus 5-FU, no LV, and decreased IRI). Radiation was used based on response and intended surgery. Charts were retrospectively reviewed to assess response, toxicities, and extent of resection when possible. Results: The most common grade 3/4 toxicity was diarrhea in six patients (14 %) with no grade 3/4 neutropenia or thrombocytopenia. Resection was attempted in 31 cases (72 %) and accomplished in 22 cases (51.1 %) including 11 of 25 LAPC cases (44 %). Vascular resection was required in 4 cases (18 %), with R0 resection in 86.4 % of the resections. Complications occurred in 6 cases (27 %), with no perioperative deaths. The median progression-free survival period was 18 months if the resection was achieved compared with 8 months if no resection was performed (p < 0.001). Conclusion: Neoadjuvant mFOLFIRINOX is an effective, well-tolerated regimen for patients with advanced nonmetastatic pancreatic cancer. When mFOLFIRINOX is coupled with aggressive surgery, high resection rates are possible even when the initial imaging shows locally advanced disease. Although data are still maturing, resection appears to offer at least a progression-free survival advantage.

UR - http://www.scopus.com/inward/record.url?scp=84923848673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923848673&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-4225-1

DO - 10.1245/s10434-014-4225-1

M3 - Article

C2 - 25358667

AN - SCOPUS:84923848673

VL - 22

SP - 1153

EP - 1159

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -